How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
Ticker(s): IBB
Name: Dr Marlene Haffner
Institution: Haffner Associates
- Former Director of the Office of Orphan Products Development at the Food and Drug Administration (FDA) for 20+ years.
- Assisted in the development of more than 300 products in the US.
- Credited with assisting in the development of Orphan Drug Programs in Japan, the European Union, Australia and more.
Can we start with a general overview of how the FDA views rare-disease drug development, willingness to work with drug sponsors and include input from patient advocates?
Added By: joe_mccannHow is coronavirus impacting the conduct of clinical trials?
Added By: joe_mccannHow might the FDA consider clinical trials where enrollment is stopped prematurely?
Added By: joe_mccannHow might missing data be handled? Will alternative ways of collecting data, assessing patients be considered?
- Can visits be done remotely?
What has to happen for those types of data to be collected and audited?
Added By: joe_mccannHow flexible can the FDA be and still have reasonable assurance that data are reliable?
Added By: joe_mccannHi, we've heard about alternative pathways for vaccines to be licensed that have accelerated timelines vs traditional phase 1-3 pathway. (1) Are there any vaccines that have been approved using these pathways that you know of? (2) Could we see modification of these alternative pathways that may even offer an even quicker pathway to market given current pandemic? (3) Completely understanding that little to no data is available, if you have any, would be great to hear your thoughts on wide-varying opinions on hydroxychloroqine, azithromycin, BCG vaccine, other? Thanks in advance
Added By: gobind singhWhat is the current status of anti-body tests? The impact on studies, interference with measures in studies and what do we know on Covid antibodies?
Added By: userccea4246For applications or drug data sets which are boarderline on efficacy or safety due to covid issues. Say the p value on the primary isn’t stat sig but trends positive and one (the sponsor) could argue that the miss was due to covid drop outs.
Which way do you think the fda leans in that situation? Approve or not. And is it different for safety?
Are You Interested In These Questions?
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
